Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
56.44
+0.44 (0.79%)
May 8, 2026, 4:00 PM EDT - Market closed
Xenon Pharmaceuticals Employees
As of December 31, 2025, Xenon Pharmaceuticals had 370 total employees, including 358 full-time and 12 part-time employees. The number of employees increased by 43 or 13.15% compared to the previous year.
Employees
370
Change (1Y)
43
Growth (1Y)
13.15%
Revenue / Employee
n/a
Profits / Employee
-$1,035,581
Market Cap
5.45B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 370 | 43 | 13.15% | 358 | 12 |
| Dec 31, 2024 | 327 | 68 | 26.25% | 316 | 11 |
| Dec 31, 2023 | 259 | 46 | 21.60% | 251 | 8 |
| Dec 31, 2022 | 213 | 60 | 39.22% | 203 | 10 |
| Dec 31, 2021 | 153 | 24 | 18.60% | 149 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Apellis Pharmaceuticals | 739 |
| Corcept Therapeutics | 730 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Immunovant | 362 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
XENE News
- 1 day ago - Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham - TheFly
- 2 days ago - Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20) - TheFly
- 2 days ago - Xenon Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 2 days ago - Xenon Reports Q1 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 2 days ago - Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026 - GlobeNewsWire
- 8 days ago - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Xenon to Report Q1 2026 Financial Results on May 7, 2026 - GlobeNewsWire
- 17 days ago - Xenon Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference - Transcripts